Ad is loading...
FSCVX
Price
$27.96
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
VISVX
Price
$50.61
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
Ad is loading...

FSCVX vs VISVX

Header iconFSCVX vs VISVX Comparison
Open Charts FSCVX vs VISVXBanner chart's image
Nuveen Small Cap Value C
Price$27.96
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
Vanguard Small Cap Value Index I
Price$50.61
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
FSCVX vs VISVX Comparison Chart
Loading...
View a ticker or compare two or three
VS
FSCVX vs. VISVX commentary
Nov 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FSCVX is a Buy and VISVX is a Buy.

FUNDAMENTALS
Fundamentals
VISVX has more cash in the bank: 57.6B vs. FSCVX (452M). VISVX pays higher dividends than FSCVX: VISVX (1.90) vs FSCVX (0.09). FSCVX was incepted earlier than VISVX: FSCVX (26 years) vs VISVX (27 years). FSCVX is a more actively managed with annual turnover of: 31.00 vs. VISVX (16.00). FSCVX (3000) and VISVX (3000) have matching initial minimum investment requirements. FSCVX annual gain was more profitable for investors over the last year : 33.53 vs. VISVX (30.04). VISVX return over 5 years is better than : 62.14 vs. FSCVX (52.78).
FSCVXVISVXFSCVX / VISVX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence26 years27 years-
Gain YTD20.51717.712116%
Front LoadN/AN/A-
Min. Initial Investment30003000100%
Min. Initial Investment IRAN/AN/A-
Net Assets452M57.6B1%
Annual Yield % from dividends0.091.905%
Returns for 1 year33.5330.04112%
Returns for 3 years14.1916.9284%
Returns for 5 years52.7862.1485%
Returns for 10 years74.60109.8368%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EFXT9.240.20
+2.21%
Enerflex Ltd
RVSN0.440.01
+1.60%
Rail Vision Ltd
CAG27.170.05
+0.18%
Conagra Brands
FULC2.97-0.02
-0.67%
Fulcrum Therapeutics
KYMR43.51-0.54
-1.23%
Kymera Therapeutics